Yousif Capital Management LLC Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Yousif Capital Management LLC lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 3.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,171 shares of the company’s stock after acquiring an additional 1,568 shares during the quarter. Yousif Capital Management LLC’s holdings in Moderna were worth $1,753,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Intrinsic Value Partners LLC grew its position in shares of Moderna by 91.1% in the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after purchasing an additional 24,505 shares during the last quarter. Banco Santander S.A. purchased a new stake in Moderna during the 3rd quarter worth $3,550,000. John G Ullman & Associates Inc. boosted its holdings in Moderna by 341.3% in the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after acquiring an additional 38,400 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after buying an additional 167,596 shares in the last quarter. Finally, abrdn plc raised its position in shares of Moderna by 28.1% in the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after purchasing an additional 69,360 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

NASDAQ:MRNA opened at $30.93 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a market cap of $11.90 billion, a P/E ratio of -5.31 and a beta of 1.59. The company has a fifty day moving average price of $39.77 and a 200 day moving average price of $56.76. Moderna, Inc. has a one year low of $30.70 and a one year high of $170.47.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 2,664 shares of company stock valued at $115,210. Insiders own 15.20% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on MRNA. Wolfe Research started coverage on Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price for the company. JPMorgan Chase & Co. lowered their price target on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Evercore ISI reduced their price objective on Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a research note on Monday, January 27th. Piper Sandler reiterated an “overweight” rating and set a $69.00 price objective (down from $115.00) on shares of Moderna in a research report on Monday, November 18th. Finally, Bank of America cut their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday. Four investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus price target of $66.89.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.